JPMorgan Chase & Co. Issues Pessimistic Forecast for GoodRx (NASDAQ:GDRX) Stock Price

GoodRx (NASDAQ:GDRX) had its target price reduced by equities research analysts at JPMorgan Chase & Co. from $6.00 to $5.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 63.40% from the stock’s current price.

Other analysts have also issued research reports about the stock. Mizuho lowered their target price on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $6.00 price target on shares of GoodRx in a research report on Monday, August 11th. TD Cowen decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday. UBS Group cut their target price on shares of GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. Finally, Raymond James Financial cut shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a research report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, GoodRx presently has a consensus rating of “Hold” and a consensus target price of $5.52.

GoodRx Stock Performance

Shares of NASDAQ:GDRX opened at $3.06 on Tuesday. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. GoodRx has a 1-year low of $2.95 and a 1-year high of $5.81. The stock has a market capitalization of $1.06 billion, a P/E ratio of 34.00, a P/E/G ratio of 1.56 and a beta of 1.19. The business has a 50-day moving average price of $3.95 and a two-hundred day moving average price of $4.25.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $196.03 million for the quarter, compared to analyst estimates of $195.17 million. GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The firm’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.08 EPS. GoodRx has set its FY 2025 guidance at EPS. Equities analysts predict that GoodRx will post 0.13 earnings per share for the current year.

Insider Buying and Selling at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of GoodRx stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total value of $95,084.00. The sale was disclosed in a document filed with the SEC, which is available at this link. 4.53% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On GoodRx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GDRX. Vanguard Group Inc. increased its position in shares of GoodRx by 7.3% in the third quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock valued at $38,947,000 after acquiring an additional 624,182 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in GoodRx by 4.0% during the second quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock worth $24,001,000 after buying an additional 184,734 shares during the last quarter. Petrus Trust Company LTA lifted its stake in GoodRx by 7.4% in the 1st quarter. Petrus Trust Company LTA now owns 3,167,015 shares of the company’s stock valued at $13,967,000 after purchasing an additional 216,926 shares during the last quarter. LSV Asset Management increased its position in GoodRx by 517.1% during the third quarter. LSV Asset Management now owns 2,354,581 shares of the company’s stock worth $9,960,000 after buying an additional 1,973,017 shares during the last quarter. Finally, 8 Knots Management LLC bought a new stake in GoodRx in the first quarter valued at approximately $8,106,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.